Hydroquinone

1 Products

Well-established Evidence

Approved drug US status

Ingredient Type

Spot Treatments Most common in

Evidence by concern

Melasma First-line active Hyperpigmentation Worth adding Dark Spots Worth adding How we graded these ↓

Products with Hydroquinone

Good choice hyperpigmentation

No.1

Hydroquinone Dark-Spot Treatment

Dong-A Pharm treatment

Mela Toning Cream

A genuinely effective, cheap hydroquinone dark-spot treatment — but one that demands respect. Hydroquinone fades stubborn pigment and melasma more decisively than cosmetic brighteners, yet it's a regulated medicine: use it in limited courses with mandatory daily SPF, not indefinitely, and not in pregnancy. The dated, comedogenic base (mineral oil, isopropyl myristate, parabens, BHT) is the other mark against it.

normalcombination Fragrance Free

4.1 (400)

$12.00

The full hydroquinone guide

Almost every pigment-fading ingredient you have read about — arbutin, thiamidol, tranexamic acid, kojic acid, azelaic acid — was tested against hydroquinone.

It is the comparator, the number every challenger has to beat, and forty years of melasma trials are effectively a long argument about whether anything else can match it. In September 2020 it also stopped being something Americans could buy off a shelf, which changed the conversation without changing the pharmacology.

Where the evidence stands, by concern

Evidence for an ingredient is not one grade — it differs concern by concern. Each row below was researched separately against regulatory approvals, clinical guidelines, and trials our team opened and verified; the band and dots rank how central hydroquinone is to treating that concern, from first-line therapy down to supportive care, at treatment-level doses and vehicles. A product's own grade weighs its actual formula.

Melasma First-line active Named in treatment guidelines

Evidence certainty: Promising · Delphi consensus on melasma management by international experts and pigmentary disorders society
Hyperpigmentation Worth adding Named in treatment guidelines

Evidence certainty: Limited · Treatment recommendations for acne-associated hyperpigmentation: Results of the Delphi consensus process and a literature review
Dark Spots Worth adding Early trial evidence

Evidence certainty: Emerging

How it's regulated in the US

FDA does not classify ingredients — it classifies products, by what they are sold to do. The same molecule can be a drug active in one product and a cosmetic ingredient in the next, and only the claim on the label decides which. What follows is a statement about that legal standing, not about whether it works — the evidence question is answered separately above.

Approved drug Hydroquinone is prescription-only in the US, and unusually the OTC version is not merely unapproved but unlawful: FDA states plainly that skin lightening products containing hydroquinone are not approved for over-the-counter sale. The only approved hydroquinone drug is a prescription combination cream.

melasma FDA-approved 4 percent, with tretinoin 0.05% and fluocinolone acetonide 0.01%

Approved by FDA under a New Drug Application

Permitted label wording “For the short-term treatment of moderate to severe melasma of the face”

Tri-Luma, NDA021112, is the only FDA-approved product containing hydroquinone. FDA's consumer guidance states verbatim: 'Skin lightening products containing hydroquinone are not approved for over-the-counter sale.'

Skin Product Safety — Skin Facts! What You Need to Know About Skin Lightening Products

Hydroquinone is not a cosmetic ingredient in the US at any concentration. Anything on a US shelf listing it is an unapproved drug, and the catalog should treat it as such.

Read the source

FDA — Skin lightening product safety U.S. Food and Drug Administration

For melasma, hydroquinone is the reference depigmenting agent and appears in international expert consensus on melasma management. A Cochrane-derived systematic review found 4% hydroquinone monotherapy produced complete clearance in a substantially larger share of patients than placebo, and that the FDA-approved triple combination cream — hydroquinone 4% with tretinoin 0.05% and fluocinolone acetonide 0.01% — outperforms hydroquinone alone. The evidence for other pigment problems is thinner than clinical habit implies: for post-inflammatory hyperpigmentation the mechanism is identical but the controlled endpoint-matched data are sparse, and for discrete solar lentigines the better-studied option is a mequinol/tretinoin solution in which hydroquinone appears as the comparator rather than the lead agent. In the US, the 2020 CARES Act removed unapproved OTC hydroquinone products from the market, leaving prescription 4% as the legitimate route.

How it works

Melanin production runs through tyrosinase, the rate-limiting enzyme that converts tyrosine into the precursors a melanocyte packages into pigment. Hydroquinone is structurally close enough to that substrate to occupy the enzyme and stall the reaction, which is the mechanism everyone cites — but it is not the whole account, and the rest explains both the potency and the risks. Hydroquinone also depletes glutathione, interferes with melanosome structure and formation, and at sustained exposure is selectively cytotoxic to melanocytes themselves. That last property is why it fades pigment more decisively than the gentler tyrosinase inhibitors: it is not only slowing the factory, it is damaging it. It is also why the drug is used in courses rather than indefinitely. The same enzyme is implicated in its worst adverse effect. Recent work indicates that exogenous ochronosis — the blue-grey pigmentation that can follow prolonged use — arises from tyrosinase-catalysed metabolism of hydroquinone within the skin, rather than from the older hypothesis about homogentisate dioxygenase inhibition. Pigment cells process the drug into something that deposits and stays. Practically, that means duration matters more than concentration: cycling on and off is not caution theatre, it is the way the risk is managed.

Key benefits

The most decisively effective topical depigmenting agent for melasma
Complete melasma clearance in a meaningful share of patients at 4%
Anchor of the FDA-approved triple combination cream with tretinoin and fluocinolone
Works on epidermal pigment regardless of what triggered it
Effect is not vehicle- or pH-dependent the way vitamin C is
Decades of comparative trial data make its performance genuinely predictable

Concentration & usage

Prescription strength in the US is 4%, alone or as part of the triple combination cream; 2% was the historical over-the-counter concentration before the 2020 CARES Act removed unapproved OTC products from the market. Compounded strengths above 4% exist but bring no reliable efficacy gain and raise ochronosis risk. Duration is the number that matters most: standard clinical practice is a course of three to four months followed by a break of equal or longer length, with a non-hydroquinone maintenance agent used in between. Hydroquinone oxidizes on exposure to air and light — a tube that has turned brown has partly converted to benzoquinone and should be replaced, and opaque or airless packaging is a meaningful quality signal rather than a design flourish.

Who it's for & who should be cautious

Who it's for

Melasma that has not moved under sunscreen and a gentler brightening agent is the clearest indication, particularly the mixed and epidermal presentations, and particularly when a clinician is supervising the course. It is also the reasonable escalation for stubborn post-inflammatory hyperpigmentation after acne, where the mechanism applies even though the specific trial evidence is thinner. Anyone using it should be willing to pair it with genuinely rigorous daily photoprotection — without that, hydroquinone is bailing out a boat while the leak stays open.

Who should be cautious

Continuous long-term use is the real hazard, not the drug itself: exogenous ochronosis is a blue-grey pigmentation that can be permanent and is more frequently reported in people with deeper skin tones and in the context of prolonged unsupervised use, often with high-strength unregulated products. Anyone unwilling to cycle off should choose a different agent. It is generally avoided in pregnancy and breastfeeding, where absorption data are limited and azelaic acid is the usual substitute. People with very reactive skin may find it irritating, and irritation on pigment-prone skin can itself trigger more pigment. Products obtained outside a regulated supply chain are a specific risk — the FDA has issued warning letters over unapproved skin-lightening products, and adulteration with mercury is a documented problem in that grey market.

Pairs with & conflicts

Pairs well with: Tretinoin (All-Trans Retinoic Acid), Niacinamide (Vitamin B3), Vitamin C (L-Ascorbic Acid), Azelaic Acid, Glycolic Acid (AHA), Zinc Oxide

Use with care alongside: Benzoyl Peroxide

Myths & facts

Myth: Hydroquinone bleaches the skin and permanently destroys pigment cells.

Reality: It suppresses melanin synthesis and, with sustained exposure, is cytotoxic to melanocytes — but normal treated skin repigments after the course ends, which is why melasma relapses without maintenance. 'Bleach' also implies indiscriminate lightening; hydroquinone acts on active melanocytes, which is why it fades a patch faster than surrounding skin. The genuinely permanent outcome to fear is ochronosis from prolonged use, which is a darkening, not a lightening.

Myth: Hydroquinone was banned in the US because it causes cancer.

Reality: The 2020 CARES Act reorganized how OTC drugs are regulated, and unapproved over-the-counter hydroquinone products lost their route to market as a consequence — the FDA cited adverse events including rashes, facial swelling and ochronosis, not human cancer data. Prescription 4% hydroquinone remains available and remains recommended in melasma consensus guidance. The rodent carcinogenicity findings behind much of the internet anxiety come from oral dosing at levels that have no relationship to a topical cream.

Myth: If 4% works, a compounded 8% or 10% will work twice as well.

Reality: There is no reliable efficacy dividend above 4%, and the adverse-effect curve does not flatten — ochronosis risk is associated with high-strength and prolonged exposure. The evidence-backed way to get more out of hydroquinone is combination, not concentration: the triple combination cream with tretinoin and fluocinolone beat hydroquinone alone in the Cochrane-derived analysis.

Frequently asked questions

How long can I safely use hydroquinone before taking a break?

Standard clinical practice is a course of three to four months followed by a break of at least the same length, with a non-hydroquinone agent such as azelaic acid, niacinamide or tranexamic acid holding the ground in between. Continuous open-ended use is the pattern associated with exogenous ochronosis, and cycling is how that risk is kept low.

Is hydroquinone still legal in the United States?

Prescription hydroquinone, typically 4%, remains available and in routine dermatological use. What changed in September 2020 is that unapproved over-the-counter hydroquinone products lost their legal route to market under the CARES Act, and the FDA has since sent warning letters to companies still selling them. Buying it without a prescription now generally means buying from an unregulated source.

Why did my dark patches come back after I stopped?

Hydroquinone suppresses melanin production rather than curing the tendency to make it. In melasma especially, the underlying hormonal and UV drivers are still there, so pigment returns once the brake is released. Relapse is expected, which is why treatment is usually structured as a course followed by a maintenance agent plus disciplined daily sun protection rather than as a one-time fix.

What is exogenous ochronosis and how likely is it?

It is a blue-grey or sooty darkening of treated skin, potentially permanent, that follows prolonged hydroquinone use — recent evidence points to tyrosinase-catalysed metabolism of the drug within the skin as the cause. It is uncommon with supervised short courses at 4% and is reported far more with long-term unsupervised use, especially of high-strength unregulated products. Paradoxically, it looks like the problem worsening, which delays recognition.

Should I use hydroquinone or one of the newer alternatives like thiamidol or tranexamic acid?

The newer agents are the ones being measured against hydroquinone, not the other way around, and they are usually chosen for a gentler safety profile and indefinite use rather than for beating it head-to-head. A common approach is a supervised hydroquinone course to clear, then a newer agent for maintenance during the off period — which sidesteps the duration problem entirely.

Sources

The reading behind this